A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1033 | Th1006 | Bivalirudin | FPRPGGGGNGDFEEIPEEYL Full view | 20 | Ia | Hematological,Metabolic | Angiox | The Medicines Company UK Ltd | Powder for concentrate for solution | Injection | Antithrombins | Prothrombin |
| 1151 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Helixate FS | N.A. | Sterile, stable, purified, nonpyrogenic, dried concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1152 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hemofil M | N.A. | Dry concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1389 | Th1062 | Rituximab | Heavy Chain: QVQLQQP Full view | 664 | IIa | Cancer/Immunological | Rituxan | Biogen Idec Inc., and Genentech USA, Inc | Sterile, clear, colorless, preservative-free liquid concentrate |  Intravenous administration | Antineoplastic Agents, Immunologic Factors and Antirheumatic Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
| 1466 | Th1090 | Daclizumab | QVQLVQSGAEVKKPGSSVKV Full view | 674 | IIa | Immunologicals | Zenapax | Roche | Clear, sterile, colorless concentrate for further dilution and intravenous administration | Intravenous injection | Immunosuppressive Agents | Fusion glycoprotein F0,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1584 | Th1125 | Golimumab | N.A. Full view | 0 | IIb | Immunological | Simponi Injection | N.A. | Sterile concentrated solution of the golimumab antibody | Intravenous infusion | Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor | Tumor necrosis factor |
| 1636 | Th1142 | Obinutuzumab | N.A. Full view | 0 | IIb | Cancer | Gazyva | Genentech | Sterile, clear, colorless to slightly brown, preservative free liquid concentrate | Intravenous infusion | Antineoplastic Agents | B-lymphocyte antigen CD20 |
| 1644 | Th1147 | Natalizumab | N.A. Full view | 0 | IIa | Genetic/Immunological | Tysabri | Biogen Idec Inc. | Sterile, colorless, and clear to slightly opalescent concentrate | Intravenous infusion | Immunosuppressive agents | N.A. |
| 1724 | Th1174 | Daratumumab | NA Full view | 0 | IIIc | Cancer | Darzalex | Janssen Biotech, Inc. | Solution, concentrate | Intravenous | Antineoplastic Agents | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 |
| 1808 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Kcentra | Csl Behring Ag | Nanofiltered and Lyophilized non-activated four-factor Prothrombin Complex Concentrate | Intravenous | NA | NA |
| 1829 | Th1219 | Anti-thymocyte Globulin (Rabbit) | NA Full view | 0 | IIIb | Immunological Disorders | ATG-Fresenius | Genzyme Inc. | Concentrate for solution for infusion. | Intravenous | Antibody | T-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3 |